Tarceva helps patients with genetically distinct form of lung cancer live longer
Phase II study points to importance of EGFR biomarker to identify patients who can gain exceptional survival benefits
New data show that first-line treatment with Tarceva (erlotinib) delivered exceptional survival benefits in patients with advanced lung adenocarcinoma (a form of non small cell lung cancer) with epidermal growth factor receptor (EGFR) activating mutations. Randomized Phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB-30406. Jänne, PA et al. Oral abstract presentation at ASCO. The phase II data show that Tarceva plus chemotherapy resulted in median overall survival of 39 months and Tarceva alone gave a median survival of 31.3 months. Patients with advanced lung cancer typically survive for only about 12 months with chemotherapy alone.
“The exceptional survival benefits seen when Tarceva is given to patients with advanced lung cancer that has EGFR activating mutations suggest that we may be able to make further progress against this devastating disease.” said Dr. Luis Paz-Ares, M.D., Hospital Universitario Virgen del Rocío, Seville, Spain and lead author of a recent pooled analysis of clinical outcomes in patients with NSCLC with EGFR activating mutations.
Two prospective phase III studies of Tarceva in NSCLC with EGFR activating mutations are ongoing. The EURTAC trial involves patients in Spain, Italy and France and the OPTIMAL trial involves patients in China. Both EURTAC and OPTIMAL are evaluating the efficacy of first-line Tarceva versus chemotherapy (platinum-based and gemcitabine/carboplatin, respectively) in patients with advanced NSCLC with EGFR activating mutations who have not received prior chemotherapy. Efficacy results from the OPTIMAL trial are expected in the second half of 2010 and final results of the EURTAC trial in 2011.
Most read news
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Haverhill_fever
BioMerieux Opens a Subsidiary in the Middle East, Continuing its International Growth
Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data From Phase 2 Study of ABT-450/r for Treatment of Hepatitis C

Analytica 2022: Fighting COVID-19 with combined expertise - New tools in virus research and detection

Obulytix is developing a revolutionary solution for antibiotic resistance - Spin-off has built a platform that creates new ways to tackle bacterial infections
Sarcospan, a little protein for a big problem
Ribosome
Blood_alcohol_content
UCB announces Phase 3 clinical trial program for epratuzumab in Systemic Lupus Erythematosus did not meet primary endpoint

Novel spatial-omics technology enables investigation of diseases at their early stages - How can you trace a single diseased cell in an intact brain or a human heart?
A long day for microbes, and the rise of oxygen on Earth
